Kong Yan
首页 > 学术活动 > 专家风采



Kong Yan

Positions

2008-    Assistant Research Fellow                Peking University Cancer Hospita

2013-    Associate Professor                      Peking University Cancer Hospital


Selected publications

1.Guo J,Si L,Kong Y★,Flaherty KT,Xu X,Zhu Y,Corless CL,Li L,Li H,Sheng X,Cui C,Chi Z,Li S,Han M,Mao L,Lin X, Du N, Zhang X, Li J, Wang B, Qin S, A Phase II, Open Label, Single‐arm Trial of Imatinib Mesylate in Patients with  Metastatic Melanoma Harboring c‐Kit Mutation or Amplification, J Clin Oncol, 29 (21):2904‐2909, 2011.

2.Kong Y★, Cao W, Xi X, Ma C, Cui L, He W, The NKG2D Ligand ULBP4 Binds to TCRg9d2 and Induces Cytotoxicity to Tumor Cells through Both TCRgd and NKG2D, Blood, 1 14(2):310‐317, 2009.

3.Kong Y★,Si L,Zhu Y,Xu XG,Corless CL,Flaherty K,Li L,Li H,Sheng X,Cui C,Chi Z,Li S,Han M,Mao L,Lu A,Guo J, Large Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma, Clin Cancer Res, 17(7):1684‐1691, 2011.

4.Kong Y★, Si L, Li Y, Wu X, Xu X, Dai J, Tang H, Ma M, Chi Z, Sheng X, Cui C, Guo J. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT- mTOR Pathway Inhibitors. Clin Cancer Res.  Feb 15, 22; 1018, 2016.

5.Kong Y★, Sheng X, Wu X, Yan J, Ma M, Yu J, Si L, Chi Z, Cui C, Dai J, Li Y, Yu H, Xu T, Tang H, Tang B, Mao L, Lian B, Wang X, Yan X, Li S, Guo J. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy. Clin Cancer Res. Nov 15;23(22):6946-6957,2017.

6.Dai J, Kong Y★, Si L, Chi Z, Cui C, Sheng X, Mao L, Li S, Lian B, Yang R, Liu S, Xu X, Guo J. Large‐scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib. Clin Cancer Res. 19(24): 6935‐42, 2013.

7.Bai X, Kong Y★, Chi Z, Sheng X, Cui C, Wang X, Mao L, Tang B, Li S, Lian B, Yan X, Zhou L, Dai J, Guo J, Si L.MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clin Cancer Res. Oct 15;23(20):6120-6127,2017.

8.Wang Y, Liu C, Luo M, Zhang Z, Gong J, Li J, You L, Dong L,, Chen J, Zhang J, Jia H, Kong Y#, Yu J. Chemotherapy‐induced miRNA‐29c/catenin‐δ signaling suppresses metastasis in gastric cancer. Cancer Res, Apr 1;75(7):1332‐44,2015.